Amgen and Zai Lab's trial of gastric cancer therapy meets primary endpoint

By Yahoo! Finance   |   1 week ago
Amgen and Zai Lab's trial of gastric cancer therapy meets primary endpoint

Amgen and Zai Lab's Phase III trial, FORTITUDE-101, showed that bemarituzumab with mFOLFOX6 improved overall survival in patients with unresectable gastric cancer.

Read More

Did you find this insightful?